Amgen is expected to report consensus revenue of $9.08 billion and adjusted EPS of $5.60 for the second quarter, as the stock trades at $335.50 relative to a $350.20 average price target. The primary focus for investors remains the clinical trajectory and Phase 3 trial readiness for MariTide, the company's highly anticipated dual-action obesity treatment.
Analysts are specifically looking for evidence that the core portfolio, led by the cardiovascular drug Repatha, can maintain double-digit volume growth to offset biosimilar pressures. Furthermore, management's updated full-year guidance will be scrutinized for the realized synergies following the Horizon Therapeutics integration.